Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SGN-35 in relapsed or refractory systemic anaplastic large cell lymphoma
2008-006035-12Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Dec 2008
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in anaplastic large cell lymphoma (ALCL), sponsored by Seagen Inc. Primary endpoint: Overall objective response rate (IRF). Started Dec 2008; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on 2008-006035-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006035-12.